12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Opsumit macitentan: Additional Phase III data

Additional data from the double-blind, international Phase III SERAPHIN trial in 742 patients with symptomatic PAH showed that once-daily 3 and 10 mg oral Opsumit each reduced the composite of time to first morbidity or mortality event, the primary endpoint, irrespective of background PAH therapy vs. placebo. In the presence of background PAH therapy, low-dose Opsumit reduced the risk of a morbidity or mortality event, defined as death, atrial septostomy, initiation of IV or subcutaneous prostanoids, lung transplantation or other...

Read the full 376 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >